Physician profile
Benjamin Mixon
NPI 1558558254
$1,970.38
in general payments reported to CMS, 2019-2025
22 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $49.95 · 2021: $63.14 · 2022: $130 · 2023: $524 · 2024: $359 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.32 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $318.43 | 2023-2025 | |
| Chiesi USA, INC. | $300.00 | 2025 | Ferriprox |
| Novo Nordisk INC | $286.15 | 2019-2025 | |
| Genzyme Corporation | $169.29 | 2023-2024 | |
| Csl Behring | $136.74 | 2021-2024 | Hemgenix, Afstyla, Idelvion |
| Pfizer INC. | $104.29 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $89.89 | 2022-2025 | Ultomiris |
| Servier Pharmaceuticals LLC | $78.50 | 2022-2025 | |
| Springworks Therapeutics, INC. | $72.80 | 2025 | Gomekli |
| Day One Biopharmaceuticals | $69.90 | 2024-2025 | Ojemda |
| Syndax Pharmaceuticals, INC. | $45.57 | 2025 | |
| Sobi, INC | $43.81 | 2019-2020 | |
| Hema Biologics, LLC | $35.87 | 2021-2024 | Sevenfact |
| Azurity Pharmaceuticals, INC. | $35.66 | 2022-2024 | Xatmep |
| Uswm, LLC | $33.19 | 2025 | Iwilfin |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.89 | 2020-2023 | Nplate |
| Biomarin Pharmaceutical INC. | $28.41 | 2023 | Roctavian |
| Bayer Healthcare Pharmaceuticals INC. | $21.90 | 2023 | |
| Octapharma USA, INC. | $20.44 | 2024 | Balfaxar |
| Takeda Pharmaceuticals U.S.A., INC. | $19.14 | 2024 | Vpriv |
| Novartis Pharmaceuticals Corporation | $16.21 | 2019 | |
| Genentech USA, INC. | $14.30 | 2023 | Hemlibra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Mixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.